@ARTICLE{
author={von Minckwitz Gunter,Colleoni Marco A,Kolberg Hans-Christian,Morales Serafin,Santi Patricia Xavier,Tomasevic Zorica I,Zhang Nan,Hanes Vladimir},
year={2018},
title={Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial},
journal={LANCET ONCOLOGY},
volume={19},
number={7},
pages={987-998},
document_type={Article},
} 

@ARTICLE{
author={Kolberg Hans-Christian,Tomasevic Zoran M,Demetriou Georgia S,von Minckwitz Gunter,Fujiwara Yasuhiro,Ponomarova O,Tesch Hans,Santi Patricia Xavier,Hanes Vladimir},
year={2018},
title={Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications},
journal={EUROPEAN JOURNAL OF CANCER},
volume={92},
number={},
pages={S103-S104},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Chia Stephen KL,...,Holmes Frankie Ann,Ejlertsen Bent,Delaloge Suzette,Moy Beverly,Iwata Hiroji,von Minckwitz Gunter,Mansi Janine,Barrios Carlos H,Gnant Michael,Evic Zorica Toma,Denduluri Neelima,Eparovic Robert,Kim Sung-Bae,Jakobsen Erik Hugger,Harvey Vernon,Robert Nicholas,Smith John II,Harker Graydon,Lalani Alshad S,Zhang Bo,Eli Lisa D,Buyse Marc,(broj koautora 25)},
year={2018},
title={PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+breast cancer: Correlative analyses of the phase III ExteNET trial},
journal={CANCER RESEARCH},
volume={78},
number={4},
pages={-},
document_type={Meeting Abstract},
}